Which company produces Pralsetinib?

Pralsetinib (Pralsetinib) is in clinical development by Blueprint Medicines and is currently in Phase II treatment of solid tumors. According to GlobalData, the Phase Transition Success Rate (PTSR) metric for advancing Phase II drugs into Phase III for the treatment of solid tumors is 21%. The report assesses how the drug-specific PTSR and Likelihood of Approval (LoA) scores for platinib compare to indication benchmarks.

Platinibis an anticancer drug that is formulated into hard gelatin capsules for the oral route of administration and BLU-667 works by targeting the RET receptor tyrosine kinase. Platinib is indicated for the treatment of adult patients with transfection (RET) fusion-positive non-small cell lung cancer with metastatic rearrangements; it is also indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutated medullary thyroid carcinoma and thyroid cancer (TC) who require systemic therapy, as well as patients who require systemic therapy and are refractory to radioactive iodine.

The original drug Platinib has been launched in China, but it has not yet passed the relevant policies for inclusion in medical insurance. The price of 120 pills per box may be around 60,000 yuan. The price of the European version of Platinib's original drug sold overseas may be around RMB 40,000 per box of 60 pills, and the U.S. version may be priced around RMB 150,000 per box (the price may fluctuate due to exchange rates), which is expensive. There are also generic Platinib drugs available for sale overseas. The ingredients of the drug are basically the same as those of the original drug at home and abroad. The price of 120 pills per box may be more than RMB 4,000 (the price may fluctuate due to the exchange rate).